Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 2/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5405855 | 0.78 | ALDH1A1 (0.46) | NQO2MTNR1AMTNR1BALDH1A1KDM4E | |
| SCHEMBL1093104 | 0.75 | ALDH1A1 (0.51) | ALDH1A1KDM4EMAPTALOX15ERN1 | |
| SCHEMBL8818298 | 0.74 | ALDH1A1 (0.58) | NQO2MTNR1AMTNR1BALDH1A1KDM4E | |
| SCHEMBL5071942 | 0.74 | MEN1 (0.56) | ALDH1A1KDM4EMAPTCYP3A4ALOX15 | |
| SCHEMBL19859493 | 0.73 | ALDH1A1 (0.48) | NQO2MTNR1AMTNR1BALDH1A1KDM4E | |
| SCHEMBL18498508 | 0.73 | MTNR1A (0.54) | NQO2MTNR1AMTNR1BALDH1A1KDM4E | |
| SCHEMBL14981605 | 0.72 | ALDH1A1 (0.49) | ALDH1A1KDM4EMAPTERN1KMT2A | |
| SCHEMBL18498509 | 0.72 | NQO2 (0.71) | NQO2MTNR1AMTNR1BALDH1A1KDM4E | |
| SCHEMBL27773285 | 0.71 | MEN1 (0.53) | ALDH1A1KDM4EMAPTCYP3A4ALOX15 | |
| SCHEMBL30846245 | 0.70 | MTNR1A (0.52) | NQO2MTNR1AMTNR1BALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245132-B1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC NO 41424 (GB) | 2017-10-18 | — | — | EP | claimed |
| EP-2245132-A1 | ENCAPSULATED BENEFIT AGENT | Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House (GB) | 2010-11-03 | — | — | EP | claimed |
| WO-2009103576-A1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC (GB) | 2009-08-27 | — | — | WO | claimed |
| EP-2245132-B1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC NO 41424 (GB) | 2017-10-18 | — | — | EP | disclosed |
| US-7304046-B2 | Phosphoramide compounds | PURDUE RESEARCH FOUNDATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304046-B2 | Phosphoramide compounds | PURDUE RESEARCH FOUNDATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304046-B2 | Phosphoramide compounds | PURDUE RESEARCH FOUNDATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-6831075-B2 | Administering to a host for inhibiting kinase activity a 5-heterocylcic subustituted pyrazolone derivative | CEPHALON, INC. | 2004-12-14 | — | — | US | disclosed |
| US-20040176332-A1 | Phosphoramide compounds | PURDUE RESEARCH FOUNDATION | 2004-09-09 | — | — | US | disclosed |
| US-6656926-B2 | For therapy and prophylaxis of cancer | PURDUE RESEARCH FOUNDATION | 2003-12-02 | — | — | US | disclosed |
| US-20030162775-A1 | Heterocyclic substituted pyrazolones | CEPHALON, INC. | 2003-08-28 | — | — | US | disclosed |
| US-20030008850-A1 | For therapy and prophylaxis of cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-09 | — | — | US | disclosed |
| US-6455525-B1 | Heterocyclic substituted pyrazolones | CEPHALON, INC. | 2002-09-24 | — | — | US | disclosed |
| WO-2001004130-A1 | PHOSPHORAMIDE COMPOUNDS | PURDUE RESEARCH FOUNDATION (US) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162775-A1 | Heterocyclic substituted pyrazolones | CYP3A4, CYP3A5, PDXK | NQO2 280/4885MTNR1A 4829/4885MTNR1B 4697/4885 |
| US-20040176332-A1 | Phosphoramide compounds | RB1, RRM2B, RRM1 | NQO2 560/4885MTNR1A 736/4885MTNR1B 873/4885 |
| US-20030008850-A1 | For therapy and prophylaxis of cancer | BRCA1, RRM2B, FOLR1 | NQO2 277/4885MTNR1A 48/4885MTNR1B 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.